Novel Drug Delivery Systems (NDDS) Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Novel Drug Delivery Systems (NDDS) Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The novel drug delivery systems (NDDS) Market is expected to register a CAGR of 5.97% during the forecast period (2022-2027).

The emergence of the COVID-19 pandemic had a very significant impact on the novel drug delivery systems market because it led to high investment in research for the development of effective therapeutics against COVID-19 such as vaccines. For instance, in May 2020, AstraZeneca received funding of more than USD 1 billion from the United States Health Department's Biomedical Advanced Research and Development Authority (BARDA) for the development, production, and delivery of the University of Oxford's COVID-19 vaccine. Further, many studies were referring to different novel delivery systems and positive outcomes from these studies may have a positive impact on the studied market. For instance, according to a research study published in November 2021, titled “Nanoparticles as an effective drug delivery system in COVID-19”, nanoparticles could be very useful in the drug delivery process for treating Covid-19 as numerous studies demonstrated that individuals who received medications using nanoparticles experienced extremely few negative effects. Therefore, it is expected that there will be a long-term impact of COVID-19 on the novel drug delivery systems (NDSS) market.

The growth of the global novel drug delivery market is primarily driven by the rising need for a controlled drug delivery system owing to the increasing burden of chronic diseases such as diabetes, cardiovascular, renal disease, asthma, cancer, and others, as with the increasing awareness about these diseases, the demand for effective and advanced therapeutics is increasing which is expected to drive the companies to develop novel drug delivery systems. For instance, according to a research study published in May 2020, titled “Global and regional prevalence, burden, and risk factors for carotid atherosclerosis: a systematic review, meta-analysis, and modeling study”, globally, in 2020, 28% of people aged 30-79 years had abnormal carotid intima-media thickness of 1 mm or more and around 21% of people in this age group had a carotid plaque, and 5% had carotid stenosis, which translates to about 816 million people with a carotid plaque and 58 million with carotid stenosis. This data shows a significant burden of cardiovascular diseases around the world. Similarly, the Globocan 2020 report projected that the global burden of cancer is expected to increase from 19.3 million in 2020 to 28.9 million by 2040. Hence, the high and increasing burden of chronic diseases is expected to lead the way for the development of novel drug delivery systems with the new investments and advancements in the area, and thus, the studied market is anticipated to grow over the forecast period.

Moreover, the technological advancements in the drug delivery systems and new investment by the private as well as government entities, coupled with the new product launches, collaboration, and mergers and acquisitions by the key companies in the market are further expected to boost growth in the novel drug delivery systems market. For instance, in June 2022, Gufic Biosciences Ltd. launched a novel drug delivery system, Dual Chamber Bags (DCB), and as per the company, these Dual Chamber Bags are 2-Chamber IV Bags made up of polypropylene (DEHP free) with a peelable aluminum foil allowing the storage of unstable drugs which need a reconstitution just before the administration to the patient. Therefore, owing to the above-mentioned factors, the novel drug delivery systems market is expected to grow during the forecast period. However, stringent regulatory guidelines along with product recalls and stability issues are expected to restrain the growth of the studied market over the forecast period.

Key Market TrendsOral Drug Delivery Systems Under Route of Administration Segment is Expected to Occupy a Major Share in the Studied Market

Oral medication administration methods are common. Due to its distinct features, such as continuous and controllable distribution, the convenience of administration, feasibility for solid formulations, patient compliance, cost-effectiveness, etc., the oral pathway received the most attention among the several drug delivery methods. With successful local and systemic effects, they are the most reliable routes for medication delivery and the ones that both doctors and patients prefer to use. Factors such as increasing research studies, clinical trials, and product launches by key market players are likely to increase the market growth. ​Various research studies are likely to increase the market growth. For instance, in July 2020, a research article titled “Micro and nanoscale technologies in oral drug delivery”, published in the journal of Advanced Drug Delivery Reviews discussed the strategies to advance the translation of micro and nanotechnologies into clinical trials for oral drug delivery. Such studies add to the scope of the oral drug delivery systems segment in the studied market. Clinical trials by key market players are expected to increase the market growth. For instance, in November 2020, Progenity Inc. released positive preliminary preclinical data regarding the performance of its oral drug delivery system (DDS), the DDS capsule which uses a proprietary autonomous localization technology designed to identify the ileal/ileocecal region of the gastrointestinal (GI) tract. This technology is based on anatomy, and it is designed to resist variability in physiological conditions, like pH, motility, and bacteria. The increasing diabetes population is also expected to increase the market growth of the segment. Since, oral administration of insulin has potential benefits in reducing pain and chances of skin infection, improving the portal levels of insulin, and avoiding side effects such as hyperinsulinemia, weight gain, and hypoglycemia. Thus, increasing diabetes is expected to increase the consumption of oral diabetes drugs which will increase the demand for oral drug delivery systems in the upcoming future. Product launches are another factor in market growth. For instance, in July 2020, Mayne Pharma Group Limited received the United States Food and Drug Administration (FDA)’s approval for its Abbreviated New Drug Application (ANDA) for chlorzoxazone tablets, 375 mg, 500 mg, and 750 mg, in the United States. Chlorzoxazone in tablet form is a fast-acting muscle relaxant that is indicated for painful acute musculoskeletal conditions. Thus, due to the aforementioned factors, the oral drug delivery systems segment in the novel drug delivery systems market is expected to grow and have a major share over the forecast period.

North America is Expected to Account for Largest Market Share in the Novel Drug Delivery Systems Market

North America is expected to dominate the novel drug delivery systems market. North America is leading the market, due to factors such as a rise in the number of research activities about new therapies, an increase in the budget for novel drug discovery, and growing awareness about novel drug delivery systems. Chronic diseases and conditions are on the rise in this region. For instance, according to the estimates of the GLOBOCAN in 2020, there would be 2,281,658 new cancer cases diagnosed and 612,390 deaths, due to cancer in the United States. The most common cancers in the United States are breast cancer, lung cancer, prostate cancer, colorectum cancer, bladder cancer, and skin cancer. In addition, several companies are focusing on the innovations of novel drug delivery systems, market expansion, and new product launches which are expected to fuel the market growth over the forecast period. For instance, in April 2020, Teva Pharmaceuticals USA launched the autoinjector device for AJOVY (fremanezumab-vfrm) injection in the United States, which is indicated for the preventive treatment of migraine in adults. It is the only anti-CGRP (calcitonin gene-related peptide) preventive migraine treatment with quarterly (675 mg) and monthly (225 mg) subcutaneous dosing options.​ Similarly, in March 2020, Teva Pharmaceutical Industries Ltd. launched its drug product Copaxone in the prefilled autoinjector YpsoMate from Ypsomed for the treatment of patients with relapsing forms of multiple sclerosis (MS) in 50 countries worldwide including Mexico. Hence, such product launches are expected to increase market growth. Thus, the rising patient pool of chronic disorders, and the development, and launch of technologically advanced drug delivery systems are expected to drive the novel drug delivery systems market in North America during the forecast period.

Competitive Landscape

The market studied is a consolidated market owing to the presence of major market players. The market players are focusing on the development of innovative treatment options in order to grab maximum market share. Some of the market players are Abbott Laboratories, AstraZeneca PLC, Bayer AG, F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer Inc., etc.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.